NMT1 and invasive breast carcinoma: More importantly, large sample studies (e.g., 301 cases of hepatocellular carcinoma [159] and 706 cases of BrCa [453]) consistently showed that NMT1 high-expression patients had significantly shorter overall survival and were strongly associated with poor indicators such as high tumor grade and high proliferation index, whereas NMT2 was low-expressed or functionally unassociated in most tumors [454].